Life Science Compliance Update

February

2017

Antitrust and Generic Drugs – A Rare Combination

Written by , Posted in Antitrust

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

Generic drug companies have been on the radar of the Department of Justice (“DOJ”) for several years, and recently the DOJ filed the first documents in the first suit against a generic drug manufacturer. Interestingly, they chose to start with a little-known company, after the company already went after the executives for racketeering charges. This article outlines several different actions focused on generic pharmaceutical manufacturers that are presently working their way through the courts.


   or   

Topic tags:

Menu Title